Zydus Cadila has received the final approval from the US Food & Drug Administration (USFDA) to market Budesonide Capsules, 3 mg (Enteric Coated). The drug is a corticosteroid used for its anti-inflammatory action.
Budesonide Capsules will be produced at the group’s formulations manufacturing facility at the Pharma SEZ in Ahmedabad. The estimated sales for Budesonide is $285.8 million, as per IMS MAT March 2017. The group now has more than 110 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.